Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DARLENE: Diroximel Fumarate to Reduce Perihaematomal Oedema in Intracerebral Haemorrhage
2025-522687-33-00Phase 3Authorised
- Sponsor
- CHU de Lille
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in intracerebral hemorrhage (ICH) comparing Vumerity arm with Placebo arm (2 arms). Primary endpoint: Perihaematomal oedema volume at day 8. Planned start Feb 2026; status: authorised.
02
Drugs
diroximel fumarate
03
Conditions
intracerebral hemorrhage (ICH)
Beyond the preview
Go deeper on 2025-522687-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522687-33-00.